Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815907 | 0.77 | CDK8 (0.39) | FLT1CDK8CDK9LIMK1ROCK1 | |
| SCHEMBL3758060 | 0.74 | L3MBTL1 (0.37) | FLT1CDK8CDK9LIMK1ROCK1 | |
| SCHEMBL17826559 | 0.71 | L3MBTL1 (0.35) | — | |
| SCHEMBL3767439 | 0.70 | KDM4E (0.36) | FLT1CDK8CDK9LIMK1ROCK1 | |
| SCHEMBL17812868 | 0.69 | CDK8 (0.39) | FLT1CDK8CDK9LIMK1ROCK1 | |
| SCHEMBL21849255 | 0.69 | KDM4E (0.33) | FLT1CDK8CDK9LIMK1ROCK1 | |
| SCHEMBL3754494 | 0.69 | ALDH1A1 (0.39) | FLT1CDK8CDK9LIMK1ROCK1 | |
| SCHEMBL17174248 | 0.67 | CDK8 (0.47) | FLT1CDK8CDK9LIMK1ROCK1 | |
| SCHEMBL18748604 | 0.66 | CHEK1 (0.33) | CDK8ROCK1 | |
| SCHEMBL15743345 | 0.65 | HPGDS (0.36) | FLT1CDK8CDK9LIMK1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873702-B2 | Heterocyclic compounds as biogenic amine transport modulators | SOUTHERN RESEARCH INSTITUTE (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SOUTHERN RESEARCH INSTITUTE | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159809-A1 | HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS | SLC18A2, SLC6A2, SLC6A3 | FLT1 972/4885CDK8 1965/4885CDK9 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.